Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 26, 2024; 12(3): 466-473
Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.466
Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.466
Lipid-lowering agent | Corresponding rationale in Moyamoya disease treatment |
Statins | Addressing concurrent dyslipidemia (LDL > 100) |
Facilitating collateral development post-EDAS | |
Fibrate | Literature provides no extant findings |
- Citation: Muengtaweepongsa S, Panpattanakul V. Is medical management useful in Moyamoya disease? World J Clin Cases 2024; 12(3): 466-473
- URL: https://www.wjgnet.com/2307-8960/full/v12/i3/466.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i3.466